CN101808647A - 通过抑制Gpr12治疗认知障碍的方法 - Google Patents

通过抑制Gpr12治疗认知障碍的方法 Download PDF

Info

Publication number
CN101808647A
CN101808647A CN200880023965A CN200880023965A CN101808647A CN 101808647 A CN101808647 A CN 101808647A CN 200880023965 A CN200880023965 A CN 200880023965A CN 200880023965 A CN200880023965 A CN 200880023965A CN 101808647 A CN101808647 A CN 101808647A
Authority
CN
China
Prior art keywords
gpr12
training
memory
mammal
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880023965A
Other languages
English (en)
Chinese (zh)
Inventor
M·彼得斯
R·E.·M.·斯科特
T·P.·塔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helicon Therapeutics Inc
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of CN101808647A publication Critical patent/CN101808647A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200880023965A 2007-05-15 2008-05-15 通过抑制Gpr12治疗认知障碍的方法 Pending CN101808647A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93816307P 2007-05-15 2007-05-15
US60/938,163 2007-05-15
PCT/US2008/063804 WO2008144453A1 (en) 2007-05-15 2008-05-15 Methods of treating cognitive disorders by inhibition of gpr12

Publications (1)

Publication Number Publication Date
CN101808647A true CN101808647A (zh) 2010-08-18

Family

ID=40122145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880023965A Pending CN101808647A (zh) 2007-05-15 2008-05-15 通过抑制Gpr12治疗认知障碍的方法

Country Status (11)

Country Link
US (2) US7968524B2 (enExample)
EP (1) EP2162137B1 (enExample)
JP (1) JP2010527375A (enExample)
KR (1) KR20100029079A (enExample)
CN (1) CN101808647A (enExample)
AU (1) AU2008254905A1 (enExample)
BR (1) BRPI0811625A2 (enExample)
CA (1) CA2684920A1 (enExample)
IL (1) IL202091A0 (enExample)
MX (1) MX2009012316A (enExample)
WO (1) WO2008144453A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458435A (zh) 2009-04-09 2012-05-16 考格尼申治疗股份有限公司 认知衰退的抑制剂
SG178191A1 (en) 2009-07-31 2012-03-29 Cognition Therapeutics Inc Inhibitors of cognitive decline
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
CN103458885B (zh) 2011-02-02 2016-02-10 考格尼申治疗股份有限公司 由姜黄油分离的化合物及使用方法
JP6517827B2 (ja) 2014-01-31 2019-05-22 コグニション セラピューティクス，インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
CA3061787A1 (en) 2017-05-15 2018-11-22 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
BR102022009685A2 (pt) * 2022-05-18 2023-11-28 Fundação Oswaldo Cruz Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
EP1240199A2 (en) * 1999-12-10 2002-09-18 AstraZeneca AB Method for screening of appetite control agents
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20060247194A1 (en) 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
CA2539127A1 (en) * 2003-09-19 2005-03-31 Paradigm Therapeutics Limited Receptor
EP1745295B1 (en) * 2004-04-20 2010-10-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Also Published As

Publication number Publication date
US20110281936A1 (en) 2011-11-17
US20090022667A1 (en) 2009-01-22
US7968524B2 (en) 2011-06-28
KR20100029079A (ko) 2010-03-15
CA2684920A1 (en) 2008-11-27
BRPI0811625A2 (pt) 2014-11-11
WO2008144453A1 (en) 2008-11-27
JP2010527375A (ja) 2010-08-12
AU2008254905A1 (en) 2008-11-27
EP2162137A4 (en) 2011-06-08
WO2008144453A9 (en) 2010-03-18
EP2162137B1 (en) 2016-11-23
EP2162137A1 (en) 2010-03-17
IL202091A0 (en) 2010-06-16
MX2009012316A (es) 2009-12-03

Similar Documents

Publication Publication Date Title
Sørensen et al. Gene silencing by systemic delivery of synthetic siRNAs in adult mice
KR20100017422A (ko) 작은 간섭 ＲＮＡ(ｓｉＲＮＡ)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법
CN100556461C (zh) 抗Smad7的反义寡核苷酸(ODN)及其在医药领域中的用途
Colón-Cesario et al. Knockdown of Nurr1 in the rat hippocampus: implications to spatial discrimination learning and memory
CN101808647A (zh) 通过抑制Gpr12治疗认知障碍的方法
US20100137407A1 (en) Single-chain circular rna and method of producing the same
EP1389637A1 (en) Novel forms of interfering RNA molecules
US20040147475A1 (en) Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
Spiliotis et al. Echinococcus multilocularis primary cells: improved isolation, small-scale cultivation and RNA interference
Ovsepian et al. Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors
CN102712925A (zh) 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
Taishi et al. TNFα siRNA reduces brain TNF and EEG delta wave activity in rats
CN107115352A (zh) 微rna和包含微rna的组合物
US20100105759A1 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
CN111150854A (zh) 一种改善自闭症社交障碍的方法
DK2733205T3 (en) Corticospinal upper motor neurons, methods and compositions for differentiating neural stem cells by modulating CB1 cannabinoid receptor signaling and applications thereof
CN118638786B (zh) 靶向acsl4基因的反义寡核苷酸及其应用
Duan et al. Local administration of a novel siRNA modality into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS
KR102760758B1 (ko) 기억 유연성이 향상된 마우스 및 이의 용도
CN117866959A (zh) 靶向ckip-1的双链rna分子及其用途
Tucker Using antisense morpholino oligos to knockdown gene expression in the chicken embryo
Trollope Zebrafish as a translational model of Parkinson’s disease–a study of microRNAs
CN104232640A (zh) 一种抑制Smad4基因表达的siRNA分子及其应用
WO2022138943A1 (ja) 精神疾患若しくは神経疾患のモデル非ヒト動物の製造方法、前記モデル非ヒト動物、及び、前記精神疾患若しくは神経疾患の予防又は治療剤をスクリーニングする方法
HK40025376B (zh) 靶向ckip-1的双链rna分子及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100818